FINANCE

2020 Annual Results

Information meeting of 29 March 2021

Contents

  1. Introduction Thierry CHAPUSOT
  2. Solid performances during an unprecedented crisis Thierry CHAPUSOT
  3. 2020 Annual Results

Jean-Yves SAMSON

  1. Business developments & Outlook Dominique PAUTRAT
  2. Conclusion

Thierry CHAPUSOT

2

2020 ANNUAL RESULTS - Web Conference - 29 March 2021

Qualities revealed by the crisis: agility, responsiveness and the strength of the business model

  • Financial strength:
    • A high level for Recurrent Revenue (66%) and the Gross Margin (68%).
    • Diversity of the portfolio of health-related activities.
    • An excellent balance sheet structure: €104m in cash at 31/12/2020.
    • Current bank credit facilities available: €26m.
  • The Group's ability to manage situations of crisis:
    • Anticipation and responsiveness in deploying new secure remote access and video- conferencing solutions.
    • Optimization of Human Resources: taking vacation days and other form of leave available to remain as operational as possible during the reopening face.
    • Optimization of General Expenses: cancellation of events, postponement of advertising campaigns, reducing activities and travels.
    • Inventory Management: anticipating procurement needs, prioritizing deliveries.

3

2020 ANNUAL RESULTS - Web Conference - 29 March 2021

Qualities revealed by the crisis: a high level of employee commitment combined with exceptional performances

  • The priority: ensuring the health and safety of our employees, "Corporate Citizens in the Service of Health and Well-Being".
  • An efficient and highly productive organization:
    • Business continuity during the lockdown phases:
      • Deployment of secure remote access: continuing support services to professionals.
      • Maintaining service to healthcare professional intervening in the field.
      • Customer protection solutions (OffiTeleconsult, PharmaProtect…).
    • Very strong dedication of all teams throughout the year both remotely and in the field:
      • Commercial momentum to support the launch of new offerings.
      • Fulfilment of postponed deliveries.

Annual

Current Operating

Performance

Revenue

Income

Current Operating

€171.75m

€46.65m

margin

(+8.32% vs. 2019)*

(+14.20% vs. 2019)

27.16%

(25.76% in 2019)

Stable sales (+0.49%)

like-for-like

4

2020 ANNUAL RESULTS - Web Conference - 29 March 2021

Pursuing the external growth strategy

  • Significant strategic acquisitions:

positive contribution of €12.77m to 2020 revenue

  • Integration and 100% controlling interest acquired in ICT Group.
  • Creation of MALTA BELGIUM.
  • Acquisition of a majority stake (56.27%) in PANDALAB.
  • Acquisition of ASCA INFORMATIQUE.

For information, European developments in October 2019:

  • Acquisition of a majority stake (80%) in SVEMU in Italy.
  • Acquisition of a majority stake (60%) in the German distributor I-MEDS.

5

2020 ANNUAL RESULTS - Web Conference - 29 March 2021

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Pharmagest Interactive SA published this content on 29 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 April 2021 15:01:02 UTC.